Clinical Research Directory
Browse clinical research sites, groups, and studies.
Two Dose Levels of Privigen in Pediatric CIDP
Sponsor: CSL Behring
Summary
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Official title: Randomized Study of Two Dose Levels of Privigen in Pediatric CIDP
Key Details
Gender
All
Age Range
2 Years - 17 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2019-02-28
Completion Date
2029-12-20
Last Updated
2025-10-20
Healthy Volunteers
No
Interventions
IgPro10
Normal human immunoglobulin G administered intravenously
Locations (9)
Phoenix Children's Hospital
Phoenix, Arizona, United States
Children's Hospital of Los Angeles
Los Angeles, California, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Akron Children's Hospital
Akron, Ohio, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Le Bonheur Children's Hospital
Memphis, Tennessee, United States
Neurology Rare Disease Center
Denton, Texas, United States
Children's Specialty Group
Norfolk, Virginia, United States
Seattle Children's Hospital
Seattle, Washington, United States